Materialise revenue tops €67 million as Q3 sales increase

Materialise NV (NASDAQ:MTLS) reported third-quarter 2026 revenue of €67.67 million, up 2.1% year over year, while net profit declined to €1.38 million.

Revenue growth increased to 4.9% after excluding revenue from recent divestitures in the Materialise Manufacturing segment, while adjusted EBITDA fell to €8.05 million from €8.43 million a year earlier.

“In the third quarter of this year consolidated revenue grew to EUR 67.7 million, representing 4.9% year-on-year growth when excluding last year’s revenue from the recent divestitures in our Materialise Manufacturing segment,” said Brigitte de Vet-Veithen, chief executive officer of Materialise.

Adjusted EBIT declined to €2.49 million from €2.92 million, while diluted earnings fell to €0.02 per share from €0.03 in the prior-year quarter.

Meanwhile, the company reported spending €2.28 million on share buybacks during the quarter.

The Materialise Medical segment continued to deliver double-digit revenue growth, while Manufacturing revenue, adjusted for divestitures, benefited from aerospace and defense markets, according to the company.

At September 30, 2026, Materialise's net cash position stood at €82.47 million, up €11.67 million from December 31, 2025, as the company continued investing in medical research and development and its share repurchase program.